Wednesday, 20 November 2019

Modulation of the microbiome

A Nature Review has been issued, covering the gut microbiota’s role in colorectal cancer.

According to new experimental evidence from Jun Yu’s group at The University of Hong Kong, the gut microbiota is a key cog in the formation and progression of colorectal cancer. Gut bacteria play a role in preventing adverse effects of treatment too. Clinical data demonstrated that clear changes in the number of specific bacteria are detected in patients and can even serve as a biomarker for disease screening to help to inform a patient’s response to a certain treatment. It’s clear that modulation of the gut microbiota is an excellent strategy to enhance treatment efficacy and reduce adverse effects of colorectal cancer therapies.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers